• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[干扰素与疾病]

[Interferon and diseases].

作者信息

Kita M

机构信息

Department of Microbiology, Kyoto Prefectural University of Medicine.

出版信息

Rinsho Byori. 1994 Aug;42(8):860-6.

PMID:7523746
Abstract

Interferon (IFN) is part of the body's natural defense system. IFN production is a cellular response to the foreign constituents of microbes, tumors and antigens. The three types (alpha, beta and gamma) of IFN proteins differ both structurally and antigenically and have molecular weights ranging from 16,000-25,000 daltons. The IFN proteins induce antiviral, antimicrobial, antitumor, and immunomodulatory actions. We reviewed the recent studies on the relation between IFN and diseases concerning; 1) the IFN-alpha and -gamma producing capacity in patients with cancers, liver cirrhosis, diabetes mellitus and rheumatoid arthritis, 2) endogenous IFN in sera and exudates or extracts of local lesions obtained from patients with immunological diseases such as SLE, sarcoidosis, rheumatoid arthritis, Behçet's disease, and psoriasis, 3) deletion of IFN-alpha and -beta genes in human lymphoblastoid cells lines and leukemia, and 4) the expression of IFN and other cytokine (interleukins and TNF) mRNA in normal organs under physiological conditions. Although IFNs may play an important role in cancers and immunological diseases, it is necessary to consider the interactions between IFNs and other cytokines as IFN is one of the factors involved in the cytokine network in vivo.

摘要

干扰素(IFN)是人体自然防御系统的一部分。IFN的产生是细胞对微生物、肿瘤和抗原等外来成分的反应。三种类型(α、β和γ)的IFN蛋白在结构和抗原性上都有所不同,分子量范围为16,000 - 25,000道尔顿。IFN蛋白具有诱导抗病毒、抗菌、抗肿瘤和免疫调节的作用。我们综述了近期关于IFN与疾病关系的研究,涉及:1)癌症、肝硬化、糖尿病和类风湿性关节炎患者产生IFN-α和-γ的能力;2)从系统性红斑狼疮(SLE)、结节病、类风湿性关节炎、白塞病和银屑病等免疫性疾病患者的血清、渗出液或局部病变提取物中检测到的内源性IFN;3)人类淋巴母细胞系和白血病中IFN-α和-β基因的缺失;4)生理条件下正常器官中IFN和其他细胞因子(白细胞介素和肿瘤坏死因子)mRNA的表达。尽管IFN可能在癌症和免疫性疾病中发挥重要作用,但由于IFN是体内细胞因子网络中的一个因素,有必要考虑IFN与其他细胞因子之间的相互作用。

相似文献

1
[Interferon and diseases].[干扰素与疾病]
Rinsho Byori. 1994 Aug;42(8):860-6.
2
Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.人类干扰素(IFN)介导免疫的先天性缺陷:对IFN-α/β、IFN-γ和IFN-λ在宿主防御中各自作用的见解。
Immunol Rev. 2008 Dec;226:29-40. doi: 10.1111/j.1600-065X.2008.00698.x.
3
Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients.慢性丙型肝炎病毒感染患者和非酒精性脂肪性肝炎患者肝活检中干扰素及干扰素相关基因的内源性mRNA水平。
J Med Virol. 2003 Aug;70(4):581-7. doi: 10.1002/jmv.10433.
4
Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).干扰素-γ:生物学功能与丙型肝炎病毒治疗(I/II型)(共两部分,此为第一部分)
Clin Ter. 2006 Jul-Aug;157(4):377-86.
5
[Cytokines in children with immunodeficiencies].[免疫缺陷儿童中的细胞因子]
Folia Med Cracov. 1999;40(1-2):5-97.
6
[Expression of cytokines and interferon-related genes in the mouse embryo].[小鼠胚胎中细胞因子和干扰素相关基因的表达]
C R Seances Soc Biol Fil. 1994;188(5-6):593-600.
7
Interplay between interferon and other cytokine systems in bone metabolism.干扰素与其他细胞因子系统在骨代谢中的相互作用。
Immunol Rev. 2005 Dec;208:181-93. doi: 10.1111/j.0105-2896.2005.00337.x.
8
The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in cancer.干扰素及干扰素相关因子的基因:定位及其与癌症中染色体畸变的关系
Arch Immunol Ther Exp (Warsz). 2000;48(2):95-100.
9
Interferons, interferon-like cytokines, and their receptors.干扰素、类干扰素细胞因子及其受体。
Immunol Rev. 2004 Dec;202:8-32. doi: 10.1111/j.0105-2896.2004.00204.x.
10
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].干扰素和白细胞介素与放疗联合的抗肿瘤作用。第一部分:免疫学基础
Strahlenther Onkol. 2004 Apr;180(4):187-93. doi: 10.1007/s00066-004-9119-x.